Interactions between comorbidity and treatment of chronic lymphocytic leukemia: Results of German chronic lymphocytic leukemia study group trials

Haematologica

Volumn 99, Issue 6, 2014, Pages 1095-1100

  Goede, Valentin ^a,b   Cramer, Paula ^a   Busch, Raymonde ^c   Bergmann, Manuela ^d   Stauch, Martina ^e   Hopfinger, Georg ^f   Stilgenbauer, Stephan ^d   Döhner, Hartmut ^d   Westermann, Anne ^a   Wendtner, Clemens M ^a,g   Eichhorst, Barbara ^a   Hallek, Michael ^a,b  

^a University of Cologne   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e Private Practice   (Germany)

^f PARACELSUS MEDICAL UNIVERSITY   (Austria)

^g Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; ANTINEOPLASTIC AGENT;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMORBIDITY; DISEASE ASSOCIATION; DISEASE CONTROL; FOLLOW UP; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MORTALITY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; ADULT; AGED; CANCER STAGING; FEMALE; GERMANY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; FEMALE; GERMANY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84901701451     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.096792     Document Type: Article

References (25)

1. Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol. 2011;29(5):544-50.
2. Hallek M, Pflug N. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev. 2011;25(1):1-9.
3. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al. Long term results of the fludarabine, cyclophosphamide & rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-80.
4. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74.
5. Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756-65.
6. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109(2):405-11.
7. Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, et al. A phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs. 2012;30(3):1232-40.
8. Seer. Cancer. gov [Internet]. Bethesda: NCI Surveillance, Epidemiology and End Results (SEER) Program. SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia [cited 2013 May 7]. Available from http://seer.cancer.gov/.
9. Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49(1):49-56.
10. Reyes C, Satram-Hoang S, Hoang K, Momin F, Guduru SR, Skettino S. What is the impact of comorbidity burden on treatment patterns and outcomes in elderly chronic lymphocytic leukemia patients? Blood. 2012;120(21):758.
11. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885-91.
12. Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 2009;114(16):3382-91.
13. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-7.
14. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111 (12):5446-56.
15. CTEP. Cancer. gov [Internet]. Bethesda: NCI Cancer Therapy Evaluation Program (CTEP). Retired CTC and CTCAE Versions Archive: CTC v2.0 [cited 2013 May 7]. Available from http://ctep.cancer.gov/ protocolDevelopment/electronic_applications/ ctc.htm/.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.
17. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995;43(2):130-7.
18. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441-7.
19. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, Houterman S, Verheij KD, Coebergh JW. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol. 2005;129 (5):597-606.
20. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-9.
21. Hines RB, Chatla C, Bumpers HL, Waterbor JW, McGwin G, Jr., Funkhouser E, et al. Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol. 2009;27(26): 4339-45.
22. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29(10):1335-41.
23. Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol. 2012;30(13):1447-55.
24. Read WL, Tierney RM, Page NC, Costas I, Govindan R, Spitznagel EL, et al. Differential prognostic impact of comorbidity. J Clin Oncol. 2004;22(15):3099-103.
25. Bouvet E, Borel C, Oberic L, Compaci G, Cazin B, Michallet AS, et al. Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia. Haematologica. 2013;98(1):65-70.